Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

GSK's momelotinib gains CHMP nod for myelofibrosis treatment

Published Nov 13, 2023 08:04
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
GSK
-0.36%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

British pharmaceutical company GSK has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its blood-cancer drug momelotinib. This endorsement is a critical step toward potential marketing authorization by the European Commission, which is anticipated in early 2024.

The CHMP's backing is based on encouraging data from clinical trials, including the MOMENTUM phase III study and a subset of patients from the SIMPLIFY-1 phase III trial. These studies evaluated momelotinib's safety and efficacy in treating key symptoms of myelofibrosis, a rare blood cancer characterized by an enlarged spleen, progressive anaemia, and debilitating symptoms.

Momelotinib is designed to inhibit JAK1, JAK2, and ACVR1 signalling pathways, which may improve constitutional symptoms and reduce spleen size while potentially enhancing anaemia benefits. This dual action places momelotinib as a potential first-in-class treatment option for myelofibrosis patients with moderate to severe anaemia, addressing both splenomegaly and disease-related symptoms.

The MOMENTUM trial specifically targeted symptomatic, anaemic myelofibrosis patients who had previously been treated with an approved JAK inhibitor. The study met all primary and key secondary endpoints, showing significant improvements in symptoms, spleen size response, and transfusion independence compared to danazol.

SIMPLIFY-1 compared momelotinib's effectiveness against ruxolitinib in patients who had not previously received JAK inhibitor therapy. The trial's results were focused on a subgroup of patients who presented with anaemia at baseline.

Despite the positive outcomes, common adverse reactions observed during the trials included diarrhoea, thrombocytopaenia, nausea, headache, dizziness, fatigue, asthenia, abdominal pain, and cough.

If the European Commission grants approval following this recommendation, momelotinib will be marketed under the proposed trade name Omjjara. This follows its approval in September 2023 by the U.S. Food and Drug Administration (FDA) under the brand name Ojjaara for treating intermediate or high-risk myelofibrosis in adults with anaemia.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

GSK's momelotinib gains CHMP nod for myelofibrosis treatment
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email